The Impact of COVID19 on Psoriasis PatientsNCT05381402
Impact of COVID 19 on Psoriasis Patients
An observational study of The Impact of COVID19 on Psoriasis Patients, run by Cairo University.
Trial summary
The main objective of this work is to investigate the effect of COVID-19 pandemic on psoriasis patients. This work is designed as a cross-sectional survey based on a questionnaire directed to Egyptian psoriasis patients. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- The Impact of COVID19 on Psoriasis Patients
- What is being tested?
- Questionnaire
- How many people
- 230 participants
- Where
- No sites listed yet
- Study dates
- 20 May 2022to 10 Jun 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Study population: Psoriasis patients
Who may be able to join
- Psoriaisis patients
Who cannot join
- Children
About this study
Official title: COVID 19 Impact on Psoriasis Patients, a Hospital Based Study
The main objective of this work is to investigate the effect of COVID-19 pandemic on psoriasis patients.
This work is designed as a cross-sectional survey based on a questionnaire directed to Egyptian psoriasis patients.
- Being tested
- Questionnaire
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnaireOther
Questionnaire to assess the impact of COVID 19 on psoriasis patients
What is being measured
The primary outcome is the main question the study is designed to answer.
Questionnaire
To assess the effect of COVID 19 on psoriasis disease, treatment, follow up, vaccine
Measured: 2-4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2022
- Study start20 May 2022 (estimated)
- Primary completion10 Jun 2022 (estimated)
- Study completion10 Jun 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for The Impact of COVID19 on Psoriasis PatientsStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case crossover
- Time perspective
- Retrospective
- Enrolment
- 230 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hagar El Sayed, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05381402
- Sponsor's protocol ID
- COVID 19 and psoriais patients
- Status last verified
- May 2022
- First submitted
- 18 May 2022
- Last updated
- 19 May 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- COVID 19 Impact on Psoriasis Patients, a Hospital Based Study
- ClinicalTrials.gov ID
- NCT05381402
- Acronym / sponsor ID
- COVID 19 and psoriais patients
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 230 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 20 May 2022 (estimated)
- Primary completion
- 10 Jun 2022 (estimated)
- Study completion
- 10 Jun 2022 (estimated)
- First posted
- 19 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of this work is to investigate the effect of COVID-19 pandemic on psoriasis patients.
This work is designed as a cross-sectional survey based on a questionnaire directed to Egyptian psoriasis patients.
Study design
- Observational model
- Case crossover
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Psoriasis patients
Key inclusion criteria (1 listed)
- Psoriaisis patients
Key exclusion criteria (1 listed)
- Children
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionnaireQuestionnaire to assess the impact of COVID 19 on psoriasis patients | Other | – |
Primary outcome
Questionnaire
Time frame: 2-4 weeks
To assess the effect of COVID 19 on psoriasis disease, treatment, follow up, vaccine
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2022.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of The Impact of COVID19 on Psoriasis Patients, run by Cairo University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 May 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Questionnaire (time frame: 2-4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2022.